REVEAL GENOMICS® HER2DX® Test in European Commission-funded Trial

al guidelines and establish HER2DX® as the leading biomarker for precision oncology in HER2-positive breast cancer patients.

HER2DX® is a cutting-edge genomic test developed by REVEAL GENOMICS that accurately predicts response to HER2-targeted therapies in breast cancer patients. It analyzes the genetic makeup of tumor cells to identify those most likely to benefit from HER2-targeted treatments, helping oncologists personalize treatment plans and improve patient outcomes.

The DEFINITIVE study will enroll a cohort of HER2-positive breast cancer patients who are eligible for HER2-targeted therapies. These patients will undergo HER2DX® testing to determine their likelihood of responding to these treatments. The primary endpoint of the study is to assess the concordance between HER2DX® results and treatment outcomes, with secondary endpoints including overall survival, progression-free survival, and quality of life measures.

Dr. Miguel Ángel Quintela-Fandino, Principal Investigator of the DEFINITIVE study, expressed enthusiasm for the potential impact of HER2DX® on clinical practice. He stated, “HER2DX® has shown promise in predicting response to HER2-targeted therapies in retrospective studies. This prospective trial will provide robust evidence of its clinical utility and pave the way for widespread adoption in routine clinical practice.”

The DEFINITIVE study is expected to generate valuable data that will support the regulatory approval and reimbursement of HER2DX®. If successful, HER2DX® could become a standard of care for HER2-positive breast cancer patients, offering personalized treatment recommendations based on the unique genetic profile of their tumors.

REVEAL GENOMICS is dedicated to advancing precision oncology through innovative biomarker technologies. The company’s mission is to improve cancer treatment outcomes by delivering actionable insights tailored to individual patients. HER2DX® is just one example of the cutting-edge diagnostic tools developed by REVEAL GENOMICS to support oncologists in making informed treatment decisions.

In conclusion, the DEFINITIVE study represents a significant milestone in the validation of HER2DX® as a predictive biomarker for HER2-positive breast cancer. By enrolling a diverse cohort of patients and assessing the concordance between test results and treatment outcomes, this study will generate robust evidence of HER2DX®’s clinical utility. If successful, HER2DX® could revolutionize the management of HER2-positive breast cancer, leading to more personalized and effective treatment strategies for patients worldwide.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Viewed

Featured Franchise Opportunity

Season 2 Consign

Business Services Franchises, Retail Franchises

$50ˌ000 - $100ˌ000

Arabica Coffee House

Food & Beverage Franchises

$10ˌ000 - $50ˌ000